Moderna has released its fourth quarter financial results, revealing a significant wider-than-expected loss of $1.1 billion, attributed to a rapid decline in COVID vaccine demand and scaled-back manufacturing operations. Despite reporting revenue of $1.0 billion, exceeding estimates, their earnings per share of $(2.91) fell short of predictions, causing their stock to slide by 5%. The company is navigating a tumultuous year and anticipates further challenges ahead, including layoffs and strategic adjustments in response to changing market conditions. Investors are concerned as Moderna struggles to maintain its market standing amidst a substantial drop in vaccine sales.